When it comes to prostate MRI, experience matters. Discover why choosing an expert with a proven track record can make all the difference in accurate, reliable results. keep reading
Let’s face it, guys. We’re not getting any younger. In fact, society is getting older. The Population Reference Bureau tells us that in the U.S, the number of those age 65 and up is expected to nearly double from 52 million in 2018 to 95 million by 2060... keep reading
Does PSA screening reduce PCa mortality, or doesn’t it? We know that PSA is not specific for cancer, since many prostate conditions can cause a rise in PSA blood levels. We also know that an elevated PSA can lead to a conventional TRUS-guided biopsy, and that such biopsies can either miss prostate cancer or... keep reading
Artificial Intelligence is transforming prostate MRI interpretation, making it faster and more precise. See how this breakthrough technology is elevating prostate health diagnostics. keep reading
Understanding erectile dysfunction can lead to better health and confidence. Discover five key facts about ED and how you can take control for a happier, healthier life. keep reading
I’m excited to announce news about a new way to quantify the effects of focal laser ablation (FLA) in a way that may allow us to predict long term treatment success. I was a member of a research team out of Case Western Reserve University that developed an innovative way to use MRI before, during keep reading
A prominent urologist wrote an articulate article on how the U.S. Preventive Services Task Force made a recommendation against broad PSA screening based on an oversimplification of a complex issue. He made an eloquent declaration on several ways in which urologists are “embracing strategies to preserve, or even further decrease, prostate cancer mortality while minimizing keep reading
It’s always reassuring to receive affirmation, especially when offering a leading edge medical program to prostate cancer patients. Such was the case for us at the Sperling Prostate Center with the December, 2015 publication of a UCLA Medical Center study on the value-added of multiparametric MRI during Active Surveillance (AS). The authoritative Journal of Urology keep reading
Here’s a little quiz: Which whole gland therapy for prostate cancer has the highest risk of recurrence? Radical prostatectomy Radiation therapy Cryotherapy of the whole gland HIFU of the whole gland If you answered radiation, you are correct. According to a recent article, the rate of prostate cancer coming back after conventional external beam radiation keep reading
We know that the use of Active Surveillance (AS) as a way to hold off on prostate cancer (PCa) treatment is on the rise. Concerns about overtreatment, such as doing a prostatectomy on a patient who only has a small Gleason 3+3 tumor, stem from two recognized realities: Insignificant PCa may be slow-growing (indolent) and keep reading
Until about 10 years ago, conventional prostate cancer treatments were based on the assumption that prostate cancer is a multifocal disease. All conventional treatment modalities (surgery, radiotherapy, and thermal ablation) were “radical” because they were directed at the removal or destruction of the whole gland. Such treatments, however, put urinary and sexual function at risk, keep reading
The strategy of using active surveillance (AS) is increasingly recommended to low-risk prostate cancer (PCa) patients as a way to avoid or delay overtreatment. This is a new way of thinking; before the New Millennium, PCa was assumed to be multi-focal and most men with more than 10 years of life expectancy were hurried into keep reading
At the Sperling Prostate Center, we believe family history matters, and patients who have a hereditary history of any kind of cancer, especially first degree relatives deserve special counseling. keep reading
The vast majority of published literature on prostate cancer (PCa), and also patient advocacy websites, often seem to overlook the needs of minority populations. Differences such as genetic vulnerability (suggested by higher incidence and death rates for African American men) or ethnic differences in male identity and how men relate to their bodies are not keep reading
I recently posted a summary of an Italian study showing that MRI (mpMRI) was superior to other prostate cancer tests in terms of predicting the need for a repeat biopsy after a previously negative result. mpMRI is able to show if there is a need for another biopsy. This is happy news for patients, who dread having keep reading